OrbiMed

To add a bio or update investment portfolio, please click update information.

Investment Portfolio

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

2 Sept 2025

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

Charm Therapeutics develops next generation cancer drugs designed to overcome treatment resistance, using an AI driven discovery platform to identify compounds for aggressive blood cancers such as AML.

OrbiMed

- Life Sciences
1(12 months)
orbimed.com
Update Information

More venture news

18 Feb 2026
FYLD secures a £30m Series B led by Energy Impact Partners to monitor high-risk infrastructure fieldwork with intelligence platform
Series BIndustrial
Lawhive
5 Feb 2026
Lawhive raises £45m Series B led by angel Mitch Rales to speed up legal services for consumers with AI
Series BLegal
Tem
10 Feb 2026
Tem lands £55m Series B led by Lightspeed Venture Partners to fix the energy market with transaction infrastructure
Series BEnergy

OrbiMed

Investment Portfolio

Charm Therapeutics raises £60m Series B led by NEA and SR One to advance next generation cancer drug

More venture news

FYLD secures a £30m Series B led by Energy Impact Partners to monitor high-risk infrastructure fieldwork with intelligence platform

Lawhive raises £45m Series B led by angel Mitch Rales to speed up legal services for consumers with AI

Tem lands £55m Series B led by Lightspeed Venture Partners to fix the energy market with transaction infrastructure